Podiatry — nail pathology
A non-thermal laser pathway for fungal nail, without the chair time
Erchonia systems supplied in Australia are listed on the ARTG by the sponsor.
Device claims reference published clinical studies, not marketing copy.
Supplied to physiotherapy, podiatry and chiropractic practices nationally.
Payment is completed on the encrypted RehaCare store.
Overview
Lunula is a hands-free, non-thermal low level laser system built specifically for onychomycosis. The patient places both feet in the unit and the treatment runs to a fixed protocol — no handpiece to hold, no heat, no debridement burden on the practitioner. For podiatry clinics, the significance is operational as much as clinical: the treatment room keeps running while the device works.
Low level laser output means no heating of the nail plate or bed, so there is no thermal discomfort and no anaesthetic requirement.
Both feet are treated simultaneously in a fixed cycle. The practitioner sets the protocol and moves on.
Because positioning is fixed by the unit rather than by hand, treatment delivery does not vary between operators or sessions.
Supplied, installed, serviced and supported in Australia by RehaCare as the authorised Erchonia distributor.
How it works
The patient sits with both feet inside the unit. No debridement of the nail plate is required before treatment and no anaesthetic is used.
Two low level laser wavelengths sweep the nail bed on a rotating gantry for the programmed cycle, treating both feet at once with no operator input.
Treatments are delivered as a course over several weeks, with clearance assessed against nail growth rather than immediate appearance.
Specifications
Clinical trial results
0
Thermal adverse events reported
Non-thermal output across published Lunula trial data.
2
Wavelengths delivered
Dual low level laser wavelengths on a rotating gantry.
Both feet
Treated per cycle
Hands-free operation frees the practitioner during treatment.
Evidence
Erchonia builds its indications on randomised, double-blind, multi-centre, placebo-controlled trials — the same standard applied to pharmaceutical review — so the claims you make in clinic are defensible.
Multi-site RCT, placebo-controlled, blinded assessment
Participants with mild to moderate onychomycosis received a course of Lunula treatments or a sham protocol, with clear nail growth measured against baseline photography at follow-up.
Reported outcome. Treated nails showed a statistically significant increase in clear nail growth over sham at follow-up, with no reported thermal adverse events.
Prospective clinical series with mycological sampling
Treated nails were assessed for both visible clearance and laboratory mycological response following a standard treatment course.
Reported outcome. Improvement in clear nail was reported alongside a favourable safety profile, with no anaesthetic or debridement requirement.
Study summaries describe the design and reported outcomes of trial work submitted by Erchonia in support of its device clearances. Full study copies and regulatory documentation are available to practitioners on request. Nothing here is patient-facing advertising or a claim of individual results.
Laser vs LED
Erchonia has always used LEDs as the placebo device in its randomised, double-blind, multi-centre, placebo-controlled clinical trials, to prove the efficacy of true cold lasers over LEDs.
Don't devalue your practice with cheap, at-home LEDs. A clinic-grade laser is what separates a billable clinical intervention from a consumer gadget your patients can buy online.
Reported outcomes from randomised, double-blind, placebo-controlled trial arms, with an LED array used as the placebo device.
| LED vs laser | Red Only | Red & Violet | Green & Violet | LED (placebo group) |
|---|---|---|---|---|
| Subjects (n) | 43 | 44 | 43 | 43 |
| Duration of pain (months) | 61.7 | 76.58 | 89.19 | 82 |
| Subjects meeting study success criteria (≥ 30% pain reduction) | 65% | 75% | 81% | 11% |
| Improvement in pain, baseline to immediately after treatment | 48% | 45% | 52% | 8% |
| Improvement in range of motion (°) | 14% | 29% | 32% | 2% |
Figures as reported by Erchonia from placebo-controlled clinical trials. Individual results vary; refer to the published studies for full methodology.
Practice fit
Lunula suits clinics with a recurring nail caseload and a room that can host a fixed-position unit. Throughput is the deciding factor: because the practitioner is not tied to the device, a busy list absorbs the treatment cycles without losing consult capacity.
A single-room practice with a low nail caseload will not recover the floor space. If your fungal nail presentations are occasional rather than routine, a handheld system with broader indications is usually the better first device.
Device selection
Two questions narrow five systems down to the one or two worth a demonstration. This is a starting point, not a prescription — our clinical team will still walk your caseload before anything is quoted.
Choose what you treat to see a recommendation.
Lunula is a room-level decision as much as a device decision. These questions let our clinical team answer on your actual caseload rather than a specification sheet.
Already know what you need? Browse the RehaCare store for consumables and in-stock clinical ranges.
Lunula Laser enquiry
